<DOC>
	<DOC>NCT01517412</DOC>
	<brief_summary>Primary Objective: - To compare the two treatment regimens in terms of change of glycosylated hemoglobin (HbA1c) from baseline to endpoint (Week 24) Secondary Objective: - To assess the effect of the 2 lixisenatide regimens on: - The percentage of participants who reached the target of HbA1c &lt; 7% or ≤ 6.5% at Week 24 - Fasting Plasma Glucose (FPG) - 7-point Self-Monitored Plasma Glucose (SMPG) profiles - Body weight - To assess the safety and tolerability of the 2 lixisenatide regimens</brief_summary>
	<brief_title>Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin</brief_title>
	<detailed_description>The maximum study duration was 28 weeks per participant, including a 24-week randomized treatment period.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criteria: Participants with type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit Metformin treatment at a stable dose of at least 1.5 g/day for at least 3 months prior to screening visit. Exclusion criteria: Screening HbA1c &lt; 7.0% and &gt; 10.0% Fasting plasma glucose at screening &gt; 250 mg/dL (&gt; 13.9 mmol/L) Treatment with glucoselowering agent(s) other than metformin in a period of 3 months prior to screening, previous use of insulin Participants who usually did not eat breakfast Type 1 diabetes mellitus Body Mass Index (BMI) ≤ 20 kg/m^2 and &gt; 40 kg/m^2 Pregnancy or lactation, women of childbearing potential with no effective contraceptive method Amylase and/or lipase &gt; 3 times the upper limit of the normal laboratory range ( ULN) at screening Alanine aminotransferase (ALT) &gt; 3 ULN at screening Calcitonin ≧ 20 pg/ml (5.9 pmol/L) at screening History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy. Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes) Any contraindication related to metformin Any previous treatment with lixisenatide The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>